7.9 KB · ⇊ 6 parts · ⤓ Micron 7.9 KB · ⤓ HTML 220.8 KB

top

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism.cite-ref-adisinsight-1-2[1]cite-ref-synapse-2-1[2]cite-ref-lophora2024-3-0[3] Its route of administration has not been specified.cite-ref-adisinsight-1-3[1]

The drug acts as a selective agonist of the serotonin 5-HT2A receptor.cite-ref-adisinsight-1-4[1]cite-ref-synapse-2-2[2]cite-ref-lophora2024-3-1[3] It is said to be an analogue of LPH-5 with similar characteristics but with faster metabolism and a shorter duration of action.cite-ref-lophora2024-3-2[3] LPH-5 is a highly selective serotonin 5-HT2A receptor agonist that is under development for major depressive disorder and has shown antidepressant-like effects in animals.cite-ref-rorstedjensensmits2024-4-0[4]cite-ref-adisinsight-lph-5-5-0[5]cite-ref-jensencecchihibicke2024-6-0[6]

LPH-48 is under development by Lophora.cite-ref-adisinsight-1-5[1]cite-ref-synapse-2-3[2] As of May 2024, it is in preclinical research for alcoholism.cite-ref-adisinsight-1-6[1]cite-ref-synapse-2-4[2] The chemical structure of LPH-48 does not yet seem to have been disclosed.cite-ref-adisinsight-1-7[1] However, Lophora has patented selective serotonin 5-HT2A receptor agonists for treatment of depressioncite-ref-jp7566021b2-7-0[7] and the company is said to have patent protection for LPH-48.cite-ref-adisinsight-1-8[1] Additionally, the structure of its close analogue LPH-5 is known and this compound is a phenylpiperidine derivative.cite-ref-rorstedjensensmits2024-4-1[4]

• See also

• References

• External links

• 3-Phenylpiperidine

• BMB-202

cite-note-adisinsight-11. "LPH 48". AdisInsight. 22 May 2024. Retrieved 30 October 2024. LPH 48 is a ligand therapeutic which has a similar pharmacological profile as psilocybin with superior selectivity and shorter duration, being developed by [...]

cite-note-synapse-22. "Delving into the Latest Updates on LPH-48 with Synapse". Synapse. 19 September 2024. Retrieved 30 October 2024.

cite-note-lophora2024-33. ↑ citereflophora2024Lophora (31 May 2024). "Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for Lead CNS Drug LPH-5" (PDF). Retrieved 30 October 2024. About LPH-48: LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. LPH-48 is designed as a fast-follower that shows significantly faster metabolism, indicating a shorter duration of action in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and is therefore endowed with the same optimized characteristics including favorable drug-like properties and a safe pharmacological profile.

cite-note-rorstedjensensmits2024-44. ↑ citerefm-ro-rstedjensensmitsfrydenvang2024M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (May 2024). "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 67 (9): 7224–7244. doi:10.1021/acs.jmedchem.4c00082. PMC 11089506. PMID 38648420.

cite-note-adisinsight-lph-5-55. ↑ "LPH 5". AdisInsight. 7 March 2023. Retrieved 30 October 2024.

cite-note-jensencecchihibicke2024-66. ↑ citerefjensencecchihibickebach2024Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Marcher-Rorsted E, et al. (22 April 2024). "The selective 5-HT2Areceptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents". bioRxiv. Cold Spring Harbor Laboratory. doi:10.1101/2024.04.19.590212.

cite-note-jp7566021b2-77. ↑ citerefkristensen-jl-jensen-aa-m-rcher-r-rsted-e-leth-petersen-s2021WO 2021/089824, Kristensen JL, Jensen AA, Märcher-Rørsted E, Leth-Petersen S, "5-HT2A agonists for use in treatment of depression", published 14 May 2021, assigned to Lophora ApS

• LPH-48 - Lophora

• Pipeline - Lophora

• FAQ - Lophora